URGN
UroGen Pharma Ltd.
$29.40
+10.57%
2026-05-08
About UroGen Pharma Ltd.
UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasive bladder cancer (NMIBC); and Jelmyto for pyelocalyceal solutions. The company's lead product candidates are UGN-103, which is in phase 3 of clinical trial for intravesical solution; and UGN-104 that is in phase 3 of clinical trial for pyelocalyceal solution designed for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk NMIBC. It is also developing UGN-301, UGN-301+UGN 201, and UGN-301+gemcitabine that are in phase 1 of clinical trial for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 and UGN-104. UroGen Pharma Ltd. was incorporated in 2004 and is headquartered in Princeton, New Jersey.
Key Fundamentals
Forward P/E
22.77
EPS (TTM)
$-2.74
Revenue Growth (YoY)
151.6%
Profit Margin
-94.8%
Beta
1.59
Market Cap
$1.35B
Avg Volume (10D)
883K
Recent Breakout Signals
No recent breakout signals detected for URGN.
Recent Price Range (60 Days)
60D High
$30.45
60D Low
$16.55
Avg Volume
854K
Latest Close
$29.40
Get breakout alerts for URGN
Sign up for Breakout Scanner to receive daily notifications when URGN triggers breakout signals. Build custom AI screeners and backtest strategies.
Start Free Trial7-day free trial. No card required.
UroGen Pharma Ltd. (URGN) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors URGN daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. URGN operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.